港股異動 | 信義玻璃(00868.HK)高開近5% 2021年度預盈109億-119億港元 同比增長70%-85%
格隆匯12月21日丨信義玻璃(00868.HK)高開近5%,報18港元,總市值725億港元。信義玻璃公佈,截至2021年12月31日止年度公司權益持有人應占綜合純利金額預期較截至2020年12月31日止年度的純利64億港元,增加70%至85%,至109億港元與119億港元的範圍。由於中國建築行業對浮法玻璃需求強大,因此截至2021年12月31日止年度浮法玻璃業務的平均銷售價格及銷售量較去年同期大幅提升。此外,公司的一間聯營公司,信義光能控股有限公司所貢獻的盈利有所增加。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.